Sanofi: Multiple Myeloma trials
The registry lists 39 Multiple Myeloma studies with Sanofi as lead sponsor. 3 are open to participants now and 13 have results posted.
Phase 1 13Phase 2 17Phase 3 7No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory MyelomaRecruitingNCT06630806Phase 1
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationNCT05669989Phase 2
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolRecruitingNCT04643002Phase 1/2
- SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMActive, not recruitingNCT05405166Phase 3Results posted
- Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma PatientsCompletedNCT03275285Phase 3Results posted
- Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsCompletedNCT03194867Phase 1/2Results posted
- Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsCompletedNCT02990338Phase 3Results posted
- Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma PatientsCompletedNCT02812706Phase 1/2Results posted
- Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for TransplantationTerminatedNCT00396383Phase 2Results posted
- AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/AttemptsCompletedNCT00396331Phase 2Results posted
- AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSFCompletedNCT00396266Phase 2Results posted
- AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF AloneTerminatedNCT00395967Phase 2Results posted
- Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322842Phase 2Results posted
- Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322491Phase 2Results posted
- Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma PatientsCompletedNCT00322387Phase 2Results posted
- Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsCompletedNCT00103662Phase 3Results posted
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT06356571Phase 2
- A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)TerminatedNCT05839626Phase 1
- A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05704049Phase 2
- A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT04458831
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple MyelomaActive, not recruitingNCT04270409Phase 3
- Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04045795Phase 1
- First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple MyelomaCompletedNCT04000282Phase 1
- Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03733717Phase 1
- A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantActive, not recruitingNCT03319667Phase 3
- A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple MyelomaCompletedNCT02514668Phase 1
- Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
- SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompletedNCT02283775Phase 1
- Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple MyelomaCompletedNCT02221479Phase 2
- An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem CellsCompletedNCT01753453Phase 2
- SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsCompletedNCT01749969Phase 1
- Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous TransplantationCompletedNCT01738373
- Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving PlerixaforCompletedNCT01362972
- Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple MyelomaCompletedNCT01233895Phase 1
- A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).CompletedNCT00838357Phase 3
- Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).CompletedNCT00741780
- This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.No longer availableNCT00720603
- Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
- Efficacy Study of ZD6474 to Treat Multiple Myeloma CancerCompletedNCT00047788Phase 2